Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes
- 31 October 2005
- journal article
- research article
- Published by Elsevier BV in Diabetes Research and Clinical Practice
- Vol. 70 (1), 53-62
- https://doi.org/10.1016/j.diabres.2005.02.011
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trialDiabetic Medicine, 2005
- Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes/Metabolism Research and Reviews, 2005
- Efficacy and Safety of PioglitazoneVersusMetformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized TrialJournal of Clinical Endocrinology & Metabolism, 2004
- One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 DiabetesDiabetes Care, 2004
- Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled studyAmerican Journal Of Medicine, 2001
- Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled studyClinical Therapeutics, 2000
- Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonistsJCI Insight, 2000
- Infant Pneumococcal VaccineJama-Journal Of The American Medical Association, 2000
- Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded DefinitionAnnual Review of Medicine, 1993
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988